Stotine milijuna zarobljenih u post-viralnoj noćnoj mori dok se znanstvenici trude pronaći lijek

Hundreds of millions of people around the world are enduring severe, long-term health issues following viral infections, as scientists work tirelessly to find effective treatments. The condition, often referred to as long COVID, chronic fatigue syndrome (ME/CFS), or related disorders, affects an estimated 400 million individuals globally. These patients experience debilitating symptoms including extreme fatigue, cognitive impairment known as brain fog, and persistent physical pain. For years, those suffering from these conditions were frequently labeled as hypochondriacs, their complaints ignored by healthcare professionals until the unprecedented scale of the 2020 coronavirus pandemic brought widespread attention to the issue. Dr. Amy Proal, a microbiologist who personally endured ME/CFS for years, has become a leading voice in understanding the underlying mechanisms of these chronic conditions. She notes that almost every type of infection, viral, bacterial, or parasitic, is linked to a subset of individuals who fail to fully recover. This realization has prompted a shift in how medical professionals approach these ailments, moving away from viewing them as isolated incidents and instead recognizing patterns that connect long COVID, post-Lyme disease, and ME/CFS through shared biological pathways. Researchers from prestigious institutions such as Yale University, Mount Sinai Hospital, and Imperial College London are collaborating to unravel the complex causes behind these conditions. Their efforts focus on identifying why some individuals develop chronic symptoms after infections while others do not. A key discovery involves the persistence of viral remnants within the body. Studies suggest that genetic fragments or residual components of the SARS-CoV-2 virus can remain hidden in tissues like the gut and brain for extended periods, continuously triggering low-level inflammation. This ongoing inflammatory response may activate dormant viruses, such as herpesviruses, leading to a cascade of immune responses that exacerbate symptoms. Another critical finding relates to autoimmune dysfunction. Researchers have observed that certain immune cells mistakenly identify the body's own tissues as foreign invaders, resulting in self-harm. Recent experiments involving mice injected with human autoantibodies demonstrated severe pain and other symptoms, reinforcing the theory that autoimmunity plays a central role in the pathophysiology of these conditions. Additional complications include vascular damage, which impairs the delivery of oxygen and nutrients to vital organs and disrupts mitochondrial function. In response to growing urgency, new federal funding has enabled more aggressive research initiatives. Clinical teams in New York and Alabama are experimenting with triple-drug antiviral combinations designed to eliminate lingering viral fragments while suppressing latent herpesviruses. Early results indicate substantial improvement in patient symptoms. Meanwhile, European medical centers are exploring targeted therapies aimed at eliminating antibody-producing cells that contribute to chronic inflammation. Despite these advances, many patients continue to receive normal results from standard blood tests, highlighting the limitations of current diagnostic methods. However, researchers believe they are gradually piecing together the biological mechanisms at play. With continued collaboration and innovation, there is hope that effective treatments will soon emerge, offering much-needed relief to those trapped in this prolonged health crisis.